Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.67 |
| ▸ | MAPT | P10636 | 5/20 | 0.67 |
| ▸ | HPGD | P15428 | 3/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.67 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | HEXA | P06865 | 4/20 | 0.65 |
| ▸ | HEXB | P07686 | 4/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.64 |
| ▸ | LTA4H | P09960 | 1/20 | 0.64 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.64 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.64 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10018574 | 0.94 | KMT2A (0.89) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL4582152 | 0.90 | MEN1 (0.82) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL13742157 | 0.87 | MEN1 (0.76) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL3850365 | 0.87 | MEN1 (0.76) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL3850328 | 0.87 | MEN1 (0.76) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL29459522 | 0.85 | KMT2A (0.73) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL5358249 | 0.85 | MEN1 (0.73) | MEN1KMT2AKDM4EALDH1A1HSD17B10 | |
| SCHEMBL877279 | 0.85 | KMT2A (0.73) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL9626265 | 0.85 | HEXA (0.83) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL3849346 | 0.85 | MEN1 (0.72) | MEN1KMT2AKDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931637-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PainCeptor Pharma Corp. (CA) | 2008-06-18 | — | — | EP | claimed |
| US-20070093474-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-04-26 | — | — | US | claimed |
| WO-2007030940-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-03-22 | — | — | WO | claimed |
| US-4598081-A | 1,3-dioxo-1H-benz(de)isoquinoline-2(3H) butyric acid, pharmacologically acceptable salts thereof and compositions containing the same for treatment of diabetes mellitus complications | NAUCHNO-ISSLEDOVATELSKY INSTITUT ENDOKRINOLOGII I OBMENA VESCHESTV (SU) | 1986-07-01 | — | — | US | claimed |
| US-12454559-B2 | Activating mitotic checkpoint control mechanisms | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2025-10-28 | — | — | US | disclosed |
| CN-119638694-A | Improved synthesis of key intermediates for KRAS G12C inhibitor compounds | 美国安进公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-119638693-A | Improved synthesis of key intermediates for KRAS G12C inhibitor compounds | 美国安进公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-115135750-B | Lactobacillus fermentum strain and composition for preventing or treating metabolic diseases containing same | GI生物群系公司 | 2024-12-24 | — | — | CN | disclosed |
| CN-119015258-A | Nucleic acid mediated delivery of therapeutic agents | 加利福尼亚大学董事会 | 2024-11-26 | — | — | CN | disclosed |
| CN-111065416-B | Hydrophilic linkers and conjugates thereof | 芬兰吉利科斯有限公司 | 2024-09-13 | — | — | CN | disclosed |
| CN-117897384-A | CDK2 inhibitors | 缆图药品公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-112165942-B | Tetrabenazine transdermal delivery device | 新凯治疗有限公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20070093474-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-04-26 | — | — | US | disclosed |
| US-20070093474-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-04-26 | — | — | US | disclosed |
| US-20070093474-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-04-26 | — | — | US | disclosed |
| WO-2007030940-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-03-22 | — | — | WO | disclosed |
| US-6787125-B1 | DISPENSING NEMATODE WORMS INTO MULTI-WELL PLATE CONTAINING CARBOXYMETHYL CELLULOSE; CONTACTING WITH CHEMICAL; DETECTING A SIGNAL INDICATING CHANGES; DRUG SCREENING; HIGH THROUGHPUT ASSAY | DEVGEN NV (BE) | 2004-09-07 | — | — | US | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| US-4598081-A | 1,3-dioxo-1H-benz(de)isoquinoline-2(3H) butyric acid, pharmacologically acceptable salts thereof and compositions containing the same for treatment of diabetes mellitus complications | NAUCHNO-ISSLEDOVATELSKY INSTITUT ENDOKRINOLOGII I OBMENA VESCHESTV (SU) | 1986-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093474-A1 | Methods of modulating neurotrophin-mediated activity | NGF, BDNF, NTRK2 | MEN1 3865/4885KMT2A 4267/4885KDM4E 4479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.